Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 17Fluorouracil 8Capecitabine 6Radiotherapy 5Leucovorin 5Albumin-Bound Paclitaxel 5Taxes 4Irinotecan 4Cisplatin 4130-nm albumin-bound paclitaxel 4Specimen Handling 3Radiotherapy, Conformal 3Docetaxel 3irinotecan sucrosofate 2dehydroftorafur 2Surgical Procedures, Operative 2Radiosurgery 2Pancreaticoduodenectomy 2Chemotherapy, Adjuvant 2Cetuximab 2trametinib 1tipifarnib 1saracatinib 1pegfilgrastim 1lanreotide 1ganitumab 1durvalumab 1conatumumab 1beta-D-glucosylisophosphoramide mustard 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Pancreatic Neoplasms × conatumumab × Clear all
NCT01017822 2013-06-24

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Radiation Therapy Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡